What is Eikon Therapeutics, Inc. 's G&A?

Eikon Therapeutics, Inc. (EIKN) reported G&A of $17.29M in Q1 2026.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Eikon Therapeutics, Inc. EIKN G&A

G&A at other companies

Travel + LeisureTNL

$121M-0.8%

Main Street CapitalMAIN

$5.4M+6.1%

HES

Hess MidstreamHESM

$7.9M+5.3%

SSR MiningSSRM

$38.48M+61.0%

NNN REITNNN

$14.11M+8.4%

Sabra HealthcareSBRA

$14.86M+16.8%

Other financials

Income statement

See full

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Balance sheet

See full

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Cash flow

See full

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Valuation

See full

Market cap$514.86M—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eikon Therapeutics, Inc. 's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eikon Therapeutics, Inc. 's G&A?: Eikon Therapeutics, Inc. (EIKN) reported G&A of $17.29M in Q1 2026.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.